These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 11534828)
1. Cellular protein alterations in colorectal cancer: p28, p53 and p65 studies. Stawińska M; Bryś M; Kiliańska ZM; Hanausek-Wataszek M; Krajewska WM Cytobios; 2001; 106 Suppl 1():43-55. PubMed ID: 11534828 [TBL] [Abstract][Full Text] [Related]
2. Heterogeneity in proliferation markers in colorectal cancer. Kressner U; Lindmark G; Gerdin B; Pahlman L; Glimelius B Anticancer Res; 1995; 15(6B):2755-61. PubMed ID: 8669859 [TBL] [Abstract][Full Text] [Related]
3. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features. Ioachim E Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860 [TBL] [Abstract][Full Text] [Related]
4. Immunoreactivity evaluation of mutant p53 gene product with DNA ploidy pattern in colorectal carcinoma. Nasif WA; El-Emshaty HM; Tabll A; Elmasry SA; Attallah AM; Gad Elhak NA Hepatogastroenterology; 2004; 51(58):1001-6. PubMed ID: 15239234 [TBL] [Abstract][Full Text] [Related]
5. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Chang SC; Lin JK; Lin TC; Liang WY Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226 [TBL] [Abstract][Full Text] [Related]
7. Expression of the p65 gene in patients with colorectal cancer: comparison with some histological typing, grading and clinical staging. Balcerczak M; Balcerczak E; Pasz-Walczak G; Kordek R; Mirowski M Eur J Surg Oncol; 2004 Apr; 30(3):266-70. PubMed ID: 15028307 [TBL] [Abstract][Full Text] [Related]
8. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up. Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236 [TBL] [Abstract][Full Text] [Related]
9. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923 [TBL] [Abstract][Full Text] [Related]
10. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Rohayem J; Diestelkoetter P; Weigle B; Oehmichen A; Schmitz M; Mehlhorn J; Conrad K; Rieber EP Cancer Res; 2000 Apr; 60(7):1815-7. PubMed ID: 10766164 [TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience. Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036 [TBL] [Abstract][Full Text] [Related]
12. Tumour 'budding' and its relationship to p53 and Bcl-2 expression in colorectal cancer. Guzińska-Ustymowicz K; Sulkowska M; Famulski W; Sulkowski S Anticancer Res; 2003; 23(1B):649-53. PubMed ID: 12680162 [TBL] [Abstract][Full Text] [Related]
13. The zinc finger protein OZF (ZNF146) is overexpressed in colorectal cancer. Ferbus D; Bovin C; Validire P; Goubin G J Pathol; 2003 Jun; 200(2):177-82. PubMed ID: 12754738 [TBL] [Abstract][Full Text] [Related]
14. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410 [TBL] [Abstract][Full Text] [Related]
15. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. van der Burg SH; Menon AG; Redeker A; Bonnet MC; Drijfhout JW; Tollenaar RA; van de Velde CJ; Moingeon P; Kuppen PJ; Offringa R; Melief CJ Clin Cancer Res; 2002 May; 8(5):1019-27. PubMed ID: 12006514 [TBL] [Abstract][Full Text] [Related]
16. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Boonsong A; Curran S; McKay JA; Cassidy J; Murray GI; McLeod HL Hum Pathol; 2002 Nov; 33(11):1114-9. PubMed ID: 12454816 [TBL] [Abstract][Full Text] [Related]
17. Cathepsin D protein levels in colorectal tumors: divergent expression patterns suggest complex regulation and function. Iacobuzio-Donahue C; Shuja S; Cai J; Peng P; Willett J; Murnane MJ Int J Oncol; 2004 Mar; 24(3):473-85. PubMed ID: 14767531 [TBL] [Abstract][Full Text] [Related]
18. Identification of hydrophobic proteins as biomarker candidates for colorectal cancer. Alvarez-Chaver P; Rodríguez-Piñeiro AM; Rodríguez-Berrocal FJ; Martínez-Zorzano VS; Páez de la Cadena M Int J Biochem Cell Biol; 2007; 39(3):529-40. PubMed ID: 17084656 [TBL] [Abstract][Full Text] [Related]
19. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer. Ahmed IA; Kelly SB; Anderson JJ; Angus B; Challen C; Lunec J Colorectal Dis; 2008 May; 10(4):344-51. PubMed ID: 17949449 [TBL] [Abstract][Full Text] [Related]
20. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer. Cheng S; Liu W; Mercado M; Ezzat S; Asa SL Endocr Relat Cancer; 2009 Jun; 16(2):455-66. PubMed ID: 19261683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]